CO147 Psychometric Analysis of the EORTC QLQ-NMIBC24 Using Data from a Global Phase 2 Randomized Trial of Erdafitinib[1] in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Category Primary study
ConferenceValue in Health
Year 2025
This article has no abstract
Epistemonikos ID: de0509a4a78b6ebfb40a3b3c22f05c7be9568c90
First added on: Apr 29, 2026